346 episodes

The International Journal of Gynecological Cancer publishes content on novel and relevant topics in the field of gynecologic cancer. IJGC Podcast features short interview segments with leading experts discussing the latest research in their respective areas. The podcasts will serve as an interactive and education experience for all our listeners.
* The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice and it is not intended to function as a substitute for a healthcare practitioner’s judgement, patient care or treatment. The views expressed by contributors are those of the speakers. BMJ does not endorse any views or recommendations discussed or expressed on this podcast. Listeners should also be aware that professionals in the field may have different opinions. By listening to this podcast, listeners agree not to use its content as the basis for their own medical treatment or for the medical treatment of others.

IJGC Podcast BMJ Podcasts

    • Health & Fitness
    • 5.0 • 6 Ratings

The International Journal of Gynecological Cancer publishes content on novel and relevant topics in the field of gynecologic cancer. IJGC Podcast features short interview segments with leading experts discussing the latest research in their respective areas. The podcasts will serve as an interactive and education experience for all our listeners.
* The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice and it is not intended to function as a substitute for a healthcare practitioner’s judgement, patient care or treatment. The views expressed by contributors are those of the speakers. BMJ does not endorse any views or recommendations discussed or expressed on this podcast. Listeners should also be aware that professionals in the field may have different opinions. By listening to this podcast, listeners agree not to use its content as the basis for their own medical treatment or for the medical treatment of others.

    p53abn and no myoinvasion endometrial cancer with Jessica Mcalpine and Amy Jamieson

    p53abn and no myoinvasion endometrial cancer with Jessica Mcalpine and Amy Jamieson

    In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Drs. Jessica Mcalpine and Amy Jamieson to discuss p53abn and no myoinvasion endometrial cancer. Dr. Jessica McAlpine is a surgeon-scientist at the University of British Columbia and BC Cancer and a Tier 1 Canada Research Chair. Dr. Amy Jamieson is a gynecologic oncologist at Vancouver General Hospital and BC Cancer and an Assistant Professor at the University of British Columbia.
     
    Highlights:
    • p53abn endometrial cancers are aggressive tumours, responsible for the majority of recurrences and death from this disease. The optimal management of patients with stage IA p53abn endometrial cancer without myometrial invasion is debated.
    • We demonstrate the recurrence rates in p53abn endometrial cancer stage IA without myometrial invasion were high at 16% and higher still with residual endometrial tumor (19%).
    • Recurrence rates in p53abn stage IA without myometrial invasion did not differ compared to p53abn stage IA with myometrial invasion, where adjuvant treatment is routinely recommended.
    • Most recurrences in patients with p53abn endometrial cancer stage IA without myometrial invasion were distant (89%) and fatal.
    • High rates of distant and unsalvageable recurrences in stage IA p53abn endometrial cancer without myometrial invasion justify a discussion about adjuvant therapy.

    • 27 min
    Mirvetuximab in Ovarian Cancer with Giorgio Bogani

    Mirvetuximab in Ovarian Cancer with Giorgio Bogani

    In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Professor Giorgio Bogani to discuss Mirvetuximab in Ovarian Cancer. Prof. Bogani serves as a consultant in gynecologic oncology at the Fondazione IRCCS Istituto Nazionale dei Tumori di Milano in Milan, Italy. He completed a research fellowship at the Mayo Clinic in Rochester, MN, USA, with a focus on endometrial cancer and gynecologic oncology. Currently, his expertise is centered on gynecological surgery and experimental medicine.
     
    Highlights:
    Mirvetuximab soravtansine-gynx is a ADC comprising a FRα-directed antibody and DM4 as payload.
    High FRα expression is noted in ~35-40% of platinum-resistant high-grade serous ovarian cancer.
    Mirvetuximab  showed an objective response rate of about 30-35% in platinum-resistant high-grade serous ovarian cancer with high FRα tumor expression.
    A promising activity mirvetuximab splus bevacizumab was observed in platinum-resistant ovarian cancer, regardless of level of FRα expression or prior bevacizumab exposure.
    Emerging data highlighted the promising role of mirvetuximab in combination with carboplatin and bevacizumab in platinum-sensitive ovarian cancer patients.

    • 26 min
    SLN in Endometrial Hyperplasia with Andrea Rosati

    SLN in Endometrial Hyperplasia with Andrea Rosati

    In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Andrea Rosati. Mr. Rosati is a consultant at the Department of Gynecologic Oncology at Fondazione Policlinico Universitario Agostino Gemelli in Rome (Italy). He is currently attending a second level master "Gynecologic Oncology International Master" at the Catholic University of the Sacred Heart (Rome, Italy) accredited as a Subspecialty Fellowship by the European Society of Gynaecological Oncology. His main interest areas are gynecological cancer, surgical anatomy, and gynecologic oncology surgery.
     
    Highlights:
    This study evaluated the prevalence of concurrent endometrial cancer in patients with pre-operative diagnoses of atypical endometrial hyperplasia undergoing hysterectomy. 
    Among 460 patients, 47.2% were found to have concurrent endometrial cancer.
    According to ESGO-ESTRO-ESP classification, 71.4%, were low-risk, 9.7% intermediate, 11.1% high to intermediate and 7.8% high-risk tumors.
    Positive Lymph node were found in 12 patients, accounting for the 7.6% of concurrent endometrial cancers who underwent SLN biopsy.
    SLN biopsy allowed for the adjustment of adjuvant therapy in 12.3% of high to intermediate-risk patients without increasing operative time or complication rates. 
     

    • 32 min
    ESGO Vulvar Cancer Guidelines 2023 with Maaike Oonk

    ESGO Vulvar Cancer Guidelines 2023 with Maaike Oonk

    In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Maaike Oonk to discuss the ESGO Vulvar Cancer Guidelines for 2023. Dr. Oonk is a gynaecological oncologist in the University Medical Center Groningen in the Netherlands. Her research focuses on new treatment options for vulvar cancer patients to improve quality of life. She is PI of the GROINSS-V studies and was chair of the 2023 ESGO vulvar cancer guidelines working group.
     
    Highlights:
    Inguinofemoral radiotherapy is a safe alternative for a lymphadenectomy in patients with micrometastasis in the sentinel node.
    In case of unilateral sentinel node involvement, it is probably safe to omit treatment of the contralateral (sentinel node negative) groin.
    Studies are ongoing on application of the sentinel node procedure in locally recurrent disease, tumors > 4cm or multifocal tumors: outside these studies, the sentinel node procedure should only be applied in patients with unifocal primary squamous cell vulvar cancer 4cm.
    In advanced disease, both primary chemoradiation and radical surgery are treatment options. The Vulcanize study is investigating the role of neoadjuvant chemotherapy in these patients.
    Given the rareness of this disease, treatment of vulvar cancer should be centralized in specialized centers.

    • 37 min
    IDEAL Framework: Robotics Innovation and Evaluation with Hani Marcus

    IDEAL Framework: Robotics Innovation and Evaluation with Hani Marcus

    In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Mr. Hani Marcus to discuss the IDEAL Framework. Mr. Marcus is a Consultant Neurosurgeon at the National Hospital for Neurology and Neurosurgery and Honorary Associate Professor at the UCL Queen Square Institute of Neurology.
     
    Highlights:
    - The development of the next generation of surgical robotics presents unique challenges in evaluation due to their complexity, integration with AI, and potential for system disruption.
    - The IDEAL (Idea, Development, Exploration, Assessment, and Long-term monitoring) Robotics colloquium suggests practical recommendations for evaluating surgical robots at different stages: development, comparative study, and clinical monitoring.
    - These recommendations are aimed at developers, clinicians, patients, and healthcare systems, considering multiple aspects like economics, training, ethics, and sustainability.

    • 34 min
    2024 IJGC Special Issue with Christina Fotopoulou, Ane Gerda Z. Eriksson, Glauco Baiocchi, and Oliver Zivanovic

    2024 IJGC Special Issue with Christina Fotopoulou, Ane Gerda Z. Eriksson, Glauco Baiocchi, and Oliver Zivanovic

    In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Drs. Christina Fotopoulou, Ane Gerda Z. Eriksson, Glauco Baiocchi, and Oliver Zivanovic to discuss the 2024 Special Issue of IJGC, “Novel Surgical Approaches in Gynecological Oncology”. Dr. Fotopoulou is the Chair of Gynaecological Cancer Surgery at the Department of Surgery and Cancer at Imperial College London, UK. She has served as an elected ESGO council member and Chair of the ESGO and BGCS guidelines committee. Dr. Eriksson is the chair of the endometrial cancer and gyn sarcoma group at the Department of Gynecologic Oncology at the Norwegian Radium Hospital. She is currently an elected ESGO Council member and chair of the ESGO accreditation committee. Dr. Eriksson also serves on the NSGO-CTU Foundation Board.  Dr. Glauco Baiocchi is the head of the Department of Gynecologic Oncology at the AC Camargo Cancer Center. He is also the president of the Brazilian Gynecologic Oncology Group – EVA Group. Oliver Zivanovic MD is a Gynecologic Oncologist and Chairman of the Department of Obstetrics and Gynecology at the Women's Heidelberg University Hospital, Germany. 
     
    Highlights:
    Surgery is the cornerstone of treatment in gynecologic oncology.
    Surgery is being incorporated and adapted to the evolving treatment landscape in gynecologic oncology. 
    This special issue highlights the opportunities of tailoring surgical approaches to individual patients both in regard to radically and novel surgical techniques. It brings together out of the box topics such as surgery for lymphedema, uterine transposition, imaging, quality of life, and medico-legal aspects. 
    All articles were written by respected and well-known experts on each topic.
    Our hope and intention is that this Special Issue will become a significant resource in surgery for gyn oncology and may support and inspire surgeons to deliver better treatment.

    • 36 min

Customer Reviews

5.0 out of 5
6 Ratings

6 Ratings

Top Podcasts In Health & Fitness

Feel Better, Live More with Dr Rangan Chatterjee
Dr Rangan Chatterjee: GP & Author
ZOE Science & Nutrition
ZOE
The Liz Earle Wellbeing Show
Liz Earle
Sliced Bread
BBC Radio 4
Movers and Shakers: a podcast about life with Parkinson's
Podot
Huberman Lab
Scicomm Media

You Might Also Like

Listen to Gynecologic Oncology
Gynecologic Oncology
SGO on the GO
The Society of Gynecologic Oncology
Gynecologic Oncology Update
Dr Neil Love
GYN Onc Oral Boards Review
K. Mueller
The Ezra Klein Show
New York Times Opinion
Modern Love
The New York Times